Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Authors:
Kimberly DaviesDana-Farber/Boston Children's Cancer and Blood Disorders Center;

Search for other papers by Kimberly Davies in
Current site
Google Scholar
PubMedClose
 MD
,
Matthew BarthRoswell Park Comprehensive Cancer Center;

Search for other papers by Matthew Barth in
Current site
Google Scholar
PubMedClose
 MD
,
Saro ArmenianCity of Hope National Medical Center;

Search for other papers by Saro Armenian in
Current site
Google Scholar
PubMedClose
 DO, MPH
,
Anthony N. AudinoThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Anthony N. Audino in
Current site
Google Scholar
PubMedClose
 MD
,
Phillip BarnetteHuntsman Cancer Institute at the University of Utah;

Search for other papers by Phillip Barnette in
Current site
Google Scholar
PubMedClose
 MD
,
Branko CuglievanThe University of Texas MD Anderson Cancer Center;

Search for other papers by Branko Cuglievan in
Current site
Google Scholar
PubMedClose
 MD
,
Hilda DingUCSD Rady Children's Hospital/UC San Diego Moores Cancer Center;

Search for other papers by Hilda Ding in
Current site
Google Scholar
PubMedClose
 MD
,
James B. FordFred & Pamela Buffett Cancer Center;

Search for other papers by James B. Ford in
Current site
Google Scholar
PubMedClose
 DO
,
Paul J. GalardyMayo Clinic Cancer Center;

Search for other papers by Paul J. Galardy in
Current site
Google Scholar
PubMedClose
 MD
,
Rebecca GardnerFred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

Search for other papers by Rebecca Gardner in
Current site
Google Scholar
PubMedClose
 MD
,
Rabi HannaCase Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Rabi Hanna in
Current site
Google Scholar
PubMedClose
 MD
,
Robert HayashiSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Robert Hayashi in
Current site
Google Scholar
PubMedClose
 MD
,
Alexandra E. KovachVanderbilt-Ingram Cancer Center;

Search for other papers by Alexandra E. Kovach in
Current site
Google Scholar
PubMedClose
 MD
,
Andrea Judit MachnitzThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Andrea Judit Machnitz in
Current site
Google Scholar
PubMedClose
 MD
,
Kelly W. MaloneyChildren's Hospital of Colorado/University of Colorado Cancer Center;

Search for other papers by Kelly W. Maloney in
Current site
Google Scholar
PubMedClose
 MD
,
Lianna MarksStanford Cancer Institute;

Search for other papers by Lianna Marks in
Current site
Google Scholar
PubMedClose
 MD
,
Kristin PageDuke Cancer Institute;

Search for other papers by Kristin Page in
Current site
Google Scholar
PubMedClose
 MD
,
Anne F. ReillyAbramson Cancer Center at the University of Pennsylvania;

Search for other papers by Anne F. Reilly in
Current site
Google Scholar
PubMedClose
 MD, MPH
,
Joanna L. WeinsteinRobert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Joanna L. Weinstein in
Current site
Google Scholar
PubMedClose
 MD
,
Ana C. XavierChildren's of Alabama/O'Neal Comprehensive Cancer Center at UAB; and

Search for other papers by Ana C. Xavier in
Current site
Google Scholar
PubMedClose
 MD
,
Nicole R. McMillianNational Comprehensive Cancer Network

Search for other papers by Nicole R. McMillian in
Current site
Google Scholar
PubMedClose
 MS, CHES
, and
Deborah A. Freedman-CassNational Comprehensive Cancer Network

Search for other papers by Deborah A. Freedman-Cass in
Current site
Google Scholar
PubMedClose
 PhD
Volume/Issue:
Volume 18: Issue 8
Online Publication Date:
Aug 2020
DOI:
https://doi.org/10.6004/jnccn.2020.0036
Restricted access

Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the treatment is complex, and patients may have many complicated supportive care issues. The NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas provide guidance regarding pathology and diagnosis, staging, initial treatment, disease reassessment, surveillance, therapy for relapsed/refractory disease, and supportive care for clinicians who treat sporadic pediatric BL and DLBCL.

Individual Disclosures for the NCCN Pediatric Aggressive Mature B-Cell Lymphomas Panel

TU1

  • Collapse
  • Expand
  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30. https://www.ncbi.nlm.nih.gov/pubmed/31912902

  • 2.

    Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology (Am Soc Hematol Educ Program) 2016;2016:589–597. https://www.ncbi.nlm.nih.gov/pubmed/27913533

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Casulo C, Friedberg JW. Burkitt lymphoma- a rare but challenging lymphoma. Best Pract Res Clin Haematol 2018;31:279–284. https://www.ncbi.nlm.nih.gov/pubmed/30213397

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Moormann AM, Snider CJ, Chelimo K. The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr Opin Infect Dis 2011;24:435–441. https://www.ncbi.nlm.nih.gov/pubmed/21885920

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Gouveia MH, Bergen AW, Borda V, et al.. Genetic signatures of gene flow and malaria-driven natural selection in sub-Saharan populations of the “endemic Burkitt Lymphoma belt”. PLoS Genet 2019;15:e1008027. https://www.ncbi.nlm.nih.gov/pubmed/30849090

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Parkin DM, Sitas F, Chirenje M, et al.. Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol 2008;9:683–692. https://www.ncbi.nlm.nih.gov/pubmed/18598933

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Ren W, Ye X, Su H, et al.. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood 2018;131:2670–2681. https://www.ncbi.nlm.nih.gov/pubmed/29545328

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Högfeldt T, Jaing C, Loughlin KM, et al.. Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. Oncol Lett 2016;12:2782–2788. https://www.ncbi.nlm.nih.gov/pubmed/27698858

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Nomura Y, Lavu EK, Muta K, et al.. Histological characteristics of 21 Papua New Guinean children with high-grade B-cell lymphoma, which is frequently associated with EBV infection. Pathol Int 2008;58:695–700. https://www.ncbi.nlm.nih.gov/pubmed/18844934

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd_key.html. Accessed November 14, 2019.

  • 11.

    Chung EM, Pavio M. Pediatric extranodal lymphoma. Radiol Clin North Am 2016;54:727–746. https://www.ncbi.nlm.nih.gov/pubmed/27265605

  • 12.

    Miron I, Miron L, Lupu VV, et al.. Silent presentation of multiple metastasis Burkitt lymphoma in a child: a case report and review of the literature. Medicine (Baltimore) 2017;96:e7518. https://www.ncbi.nlm.nih.gov/pubmed/28700504

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Iyer VK. Pediatric lymphoma diagnosis: role of FNAC, biopsy, immunohistochemistry and molecular diagnostics. Indian J Pediatr 2013;80:756–763. https://www.ncbi.nlm.nih.gov/pubmed/23925793

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Swerdlow SH, Campo E, Harris NL, et al.., eds. Burkitt Lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Vol. 2. Lyon, France: IARC; 2017 .

    • Search Google Scholar
    • Export Citation
  • 15.

    Swerdlow SH, Campo E, Harris NL, et al.., eds. Diffuse Large B-Cell Lymphoma, NOS. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Vol. 2. Lyon, France: IARC; 2017 .

    • Search Google Scholar
    • Export Citation
  • 16.

    Huang H, Liu ZL, Zeng H, et al.. Clinicopathological study of sporadic Burkitt lymphoma in children. Chin Med J (Engl) 2015;128:510–514. https://www.ncbi.nlm.nih.gov/pubmed/25673455

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Boerma EG, Siebert R, Kluin PM, et al.. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 2009;23:225–234. https://www.ncbi.nlm.nih.gov/pubmed/18923440

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Maria Murga Penas E, Schilling G, Behrmann P, et al.. Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples. Genes Chromosomes Cancer 2014;53:497–515. https://www.ncbi.nlm.nih.gov/pubmed/24590883

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Scholtysik R, Kreuz M, Klapper W, et al.. Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica 2010;95:2047–2055. https://www.ncbi.nlm.nih.gov/pubmed/20823134

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Toujani S, Dessen P, Ithzar N, et al.. High resolution genome-wide analysis of chromosomal alterations in Burkitt’s lymphoma. PLoS One 2009;4:e7089. https://www.ncbi.nlm.nih.gov/pubmed/19759907

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Akyurek N, Uner A, Benekli M, et al.. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012;118:4173–4183. https://www.ncbi.nlm.nih.gov/pubmed/22213394

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Barrans S, Crouch S, Smith A, et al.. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360–3365. https://www.ncbi.nlm.nih.gov/pubmed/20498406

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Clipson A, Barrans S, Zeng N, et al.. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res 2015;1:125–133. https://www.ncbi.nlm.nih.gov/pubmed/27347428

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Szczepanowski M, Lange J, Kohler CW, et al.. Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents. Br J Haematol 2017;179:116–119. https://www.ncbi.nlm.nih.gov/pubmed/28643426

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Johnson NA, Savage KJ, Ludkovski O, et al.. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273–2279. https://www.ncbi.nlm.nih.gov/pubmed/19597184

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Lu B, Zhou C, Yang W, et al.. Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients. Leuk Lymphoma 2011;52:2356–2364. https://www.ncbi.nlm.nih.gov/pubmed/21740296

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Perry AM, Crockett D, Dave BJ, et al.. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases. Br J Haematol 2013;162:40–49. https://www.ncbi.nlm.nih.gov/pubmed/23600716

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Snuderl M, Kolman OK, Chen YB, et al.. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34:327–340. https://www.ncbi.nlm.nih.gov/pubmed/20118770

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Tomita N, Tokunaka M, Nakamura N, et al.. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009;94:935–943. https://www.ncbi.nlm.nih.gov/pubmed/19535347

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Nicolae A, Pittaluga S, Abdullah S, et al.. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 2015;126:863–872. https://www.ncbi.nlm.nih.gov/pubmed/25999451

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Vaillant V, Reiter A, Zimmermann M, et al.. Seroepidemiological analysis and literature review of the prevalence of Epstein-Barr virus and herpesvirus infections in pediatric cases with non-Hodgkin lymphoma in Central Europe. Pediatr Blood Cancer 2019;66:e27752. https://www.ncbi.nlm.nih.gov/pubmed/30977593

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Satou A, Asano N, Nakazawa A, et al.. Epstein-Barr virus (EBV)-positive sporadic burkitt lymphoma: an age-related lymphoproliferative disorder? Am J Surg Pathol 2015;39:227–235. https://www.ncbi.nlm.nih.gov/pubmed/25321330

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Aukema SM, Theil L, Rohde M, et al.. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br J Haematol 2015;170:814–825. https://www.ncbi.nlm.nih.gov/pubmed/26104998

    • Search Google Scholar
    • Export Citation
  • 34.

    Pienkowska-Grela B, Rymkiewicz G, Grygalewicz B, et al.. Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement. Med Oncol 2011;28:1589–1595. https://www.ncbi.nlm.nih.gov/pubmed/20661666

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Wagener R, Seufert J, Raimondi F, et al.. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 2019;133:962–966. https://www.ncbi.nlm.nih.gov/pubmed/30567752

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Yanik EL, Shiels MS, Smith JM, et al.. Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States. Cancer 2017;123:4663–4671. https://www.ncbi.nlm.nih.gov/pubmed/28759103

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Lones MA, Sanger WG, Le Beau MM, et al.. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children’s Cancer Group Study CCG-E08. J Pediatr Hematol Oncol 2004;26:169–178. https://www.ncbi.nlm.nih.gov/pubmed/15125609

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Hutchison RE, Finch C, Kepner J, et al.. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons. Ann Oncol 2000;11(Suppl 1):S35–38. https://www.ncbi.nlm.nih.gov/pubmed/10707776

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Cairo MS, Sposto R, Perkins SL, et al.. Burkitt’s and Burkitt-like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience. Br J Haematol 2003;120:660–670. https://www.ncbi.nlm.nih.gov/pubmed/12588354

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Riad R, Omar W, Kotb M, et al.. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging 2010;37:319–329. https://www.ncbi.nlm.nih.gov/pubmed/19756591

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Salzburg J, Burkhardt B, Zimmermann M, et al.. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol 2007;25:3915–3922. https://www.ncbi.nlm.nih.gov/pubmed/17761975

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Cairo MS, Sposto R, Gerrard M, et al.. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012;30:387–393. https://www.ncbi.nlm.nih.gov/pubmed/22215753

    • Search Google Scholar
    • Export Citation
  • 43.

    Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332–339. https://www.ncbi.nlm.nih.gov/pubmed/7414342

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Rosolen A, Perkins SL, Pinkerton CR, et al.. Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol 2015;33:2112–2118. https://www.ncbi.nlm.nih.gov/pubmed/25940716

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Cairo MS, Gerrard M, Sposto R, et al.. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736–2743. https://www.ncbi.nlm.nih.gov/pubmed/17138821

    • Search Google Scholar
    • Export Citation
  • 46.

    Cairo M, Auperin A, Perkins SL, et al.. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br J Haematol 2018;182:859–869. https://www.ncbi.nlm.nih.gov/pubmed/29984828

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Genentech, Inc. RITUXAN® (rituximab) injection, for intravenous use. 2019. Accessed November 14, 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103705s5457lbl.pdf

    • Search Google Scholar
    • Export Citation
  • 48.

    Link MP, Shuster JJ, Donaldson SS, et al.. Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med 1997;337:1259–1266. https://www.ncbi.nlm.nih.gov/pubmed/9345074

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49.

    Gerrard M, Cairo MS, Weston C, et al.. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 2008;141:840–847. https://www.ncbi.nlm.nih.gov/pubmed/18371107

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50.

    Woessmann W, Seidemann K, Mann G, et al.. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005;105:948–958. https://www.ncbi.nlm.nih.gov/pubmed/15486066

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Patte C, Auperin A, Gerrard M, et al.. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007;109:2773–2780. https://www.ncbi.nlm.nih.gov/pubmed/17132719

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Intergroup randomized trial for children or adolescents with B-cell non Hodgkin lymphoma or B-acute leukemia: Rituximab evaluation in high risk patients. Gustave Roussy, Cancer Campus, Grand Paris; Children's Oncology Group; 2017. Accessed May 24, 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT01516580

  • 53.

    Goldman S, Smith L, Anderson JR, et al.. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia 2013;27:1174–1177. https://www.ncbi.nlm.nih.gov/pubmed/22940833

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Minard-Colin V, Auperin A, Pillon M, et al.. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen [abstract]. J Clin Oncol 2016;34.15_suppl:10507. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.10507.

    • Search Google Scholar
    • Export Citation
  • 55.

    Reiter A, Schrappe M, Tiemann M, et al.. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999;94:3294–3306. https://www.ncbi.nlm.nih.gov/pubmed/10552938

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Goldman S, Smith L, Galardy P, et al.. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol 2014;167:394–401. https://www.ncbi.nlm.nih.gov/pubmed/25066629

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Frazer JK, Li KJ, Galardy PJ, et al.. Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol 2019;185:374–377. https://www.ncbi.nlm.nih.gov/pubmed/30117142

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Meinhardt A, Burkhardt B, Zimmermann M, et al.. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol 2010;28:3115–3121. https://www.ncbi.nlm.nih.gov/pubmed/20516455

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59.

    Samochatova EV, Maschan AA, Shelikhova LN, et al.. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol 2014;36:395–401. https://www.ncbi.nlm.nih.gov/pubmed/23823112

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Meignan M, Gallamini A, Meignan M, et al.. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 2009;50:1257–1260. https://www.ncbi.nlm.nih.gov/pubmed/19544140

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Bailly C, Eugène T, Couec ML, et al.. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 2014;1:54. https://www.ncbi.nlm.nih.gov/pubmed/25593926

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Abdel Rahman H, Sedky M, Hamoda A, et al.. Role of FDG-PET scan in the management of pediatric mature B cell non-Hodgkin’s lymphoma. CCHE experience. J Egypt Natl Canc Inst 2016;28:95–99. https://www.ncbi.nlm.nih.gov/pubmed/27133974

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Bhojwani D, McCarville MB, Choi JK, et al.. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 2015;168:845–853. https://www.ncbi.nlm.nih.gov/pubmed/25382494

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Furth C, Erdrich AS, Steffen IG, et al.. Interim PET response criteria in paediatric non-Hodgkin’s lymphoma. Results from a retrospective multicenter reading. Nucl Med (Stuttg) 2013;52:148–156. https://www.ncbi.nlm.nih.gov/pubmed/23928982

    • Search Google Scholar
    • Export Citation
  • 65.

    Karantanis D, Durski JM, Lowe VJ, et al.. 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 2010;75:e68–e73. https://www.ncbi.nlm.nih.gov/pubmed/19716248

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Riad R, Omar W, Sidhom I, et al.. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphoma. Nucl Med Commun 2010;31:232–238. https://www.ncbi.nlm.nih.gov/pubmed/20032800

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Sandlund JT, Guillerman RP, Perkins SL, et al.. International pediatric non-Hodgkin lymphoma response criteria. J Clin Oncol 2015;33:2106–2111. https://www.ncbi.nlm.nih.gov/pubmed/25940725

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Jourdain A, Auperin A, Minard-Colin V, et al.. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Société Française des Cancers de l’Enfant study. Haematologica 2015;100:810–817. https://www.ncbi.nlm.nih.gov/pubmed/25724577

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Rigaud C, Auperin A, Jourdain A, et al.. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. Pediatr Blood Cancer 2019;66:e27873. https://www.ncbi.nlm.nih.gov/pubmed/31207026

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Fujita N, Mori T, Mitsui T, et al.. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer 2008;51:188–192. https://www.ncbi.nlm.nih.gov/pubmed/18428432

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Kim H, Park ES, Lee SH, et al.. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res Treat 2014;46:358–365. https://www.ncbi.nlm.nih.gov/pubmed/25043820

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Hartmann O, Pein F, Beaujean F, et al.. High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. J Clin Oncol 1984;2:979–985. https://www.ncbi.nlm.nih.gov/pubmed/6381657

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Naik S, Martinez CA, Omer B, et al.. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv 2019;3:2689–2695. https://www.ncbi.nlm.nih.gov/pubmed/31511228

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Eissa HM, Allen CE, Kamdar K, et al.. Pediatric Burkitt’s lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 2014;31:253–257. https://www.ncbi.nlm.nih.gov/pubmed/24087880

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Anoop P, Sankpal S, Stiller C, et al.. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:1882–1888. https://www.ncbi.nlm.nih.gov/pubmed/22448922

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Griffin TC, Weitzman S, Weinstein H, et al.. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;52:177–181. https://www.ncbi.nlm.nih.gov/pubmed/18816698

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Osumi T, Mori T, Fujita N, et al.. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016;63:1794–1799. https://www.ncbi.nlm.nih.gov/pubmed/27314926

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78.

    Giulino-Roth L, Ricafort R, Kernan NA, et al.. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer 2013;60:2018–2024. https://www.ncbi.nlm.nih.gov/pubmed/24038967

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Andion M, Molina B, Gonzalez-Vicent M, et al.. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol 2011;33:e89–e91. https://www.ncbi.nlm.nih.gov/pubmed/21358341

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Gross TG, Hale GA, He W, et al.. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010;16:223–230. https://www.ncbi.nlm.nih.gov/pubmed/19800015

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica 2016;101:680–687. https://www.ncbi.nlm.nih.gov/pubmed/27252513

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Lee CJ, Savani BN, Mohty M, et al.. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 2017;102:1810–1822. https://www.ncbi.nlm.nih.gov/pubmed/28883081

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Levine DR, Mandrell BN, Sykes A, et al.. Patients’ and parents’ needs, attitudes, and perceptions about early palliative care integration in pediatric oncology. JAMA Oncol 2017;3:1214–1220. https://www.ncbi.nlm.nih.gov/pubmed/28278329

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Olagunju AT, Sarimiye FO, Olagunju TO, et al.. Child’s symptom burden and depressive symptoms among caregivers of children with cancers: an argument for early integration of pediatric palliative care. Ann Palliat Med 2016;5:157–165. https://www.ncbi.nlm.nih.gov/pubmed/27199271

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Sung L, Zaoutis T, Ullrich NJ, et al.. Children’s Oncology Group’s 2013 blueprint for research: cancer control and supportive care. Pediatr Blood Cancer 2013;60:1027–1030. https://www.ncbi.nlm.nih.gov/pubmed/23255159

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Anghelescu DL, Faughnan LG, Jeha S, et al.. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:1147–1153. https://www.ncbi.nlm.nih.gov/pubmed/21319291

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Lehrnbecher T, Robinson P, Fisher B, et al.. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017;35:2082–2094. https://www.ncbi.nlm.nih.gov/pubmed/28459614

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Patel P, Robinson PD, Thackray J, et al.. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update [published online April 28, 2017]. Pediatr Blood Cancer doi: 10.1002/pbc.26542 https://www.ncbi.nlm.nih.gov/pubmed/28453189

    • Search Google Scholar
    • Export Citation
  • 89.

    Sung L, Robinson P, Treister N, et al.. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. BMJ Support Palliat Care 2017;7:7–16. https://www.ncbi.nlm.nih.gov/pubmed/25818385

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Robinson PD, Oberoi S, Tomlinson D, et al.. Management of fatigue in children and adolescents with cancer and in paediatric recipients of haemopoietic stem-cell transplants: a clinical practice guideline. Lancet Child Adolesc Health 2018;2:371–378. https://www.ncbi.nlm.nih.gov/pubmed/30169270

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Diorio C, Robinson PD, Ammann RA, et al.. Guideline for the management of clostridium difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients. J Clin Oncol 2018;36:3162–3171. https://www.ncbi.nlm.nih.gov/pubmed/30216124

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Flank J, Robinson PD, Holdsworth M, et al.. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer 2016;63:1144–1151. https://www.ncbi.nlm.nih.gov/pubmed/26960036

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Kearney JA, Salley CG, Muriel AC. Standards of psychosocial care for parents of children with cancer. Pediatr Blood Cancer 2015; 62(S5, Suppl 5)S632–S683. https://www.ncbi.nlm.nih.gov/pubmed/26700921

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Choi EK, Yoon SJ, Kim JH, et al.. Depression and distress in caregivers of children with brain tumors undergoing treatment: psychosocial factors as moderators. Psychooncology 2016;25:544–550. https://www.ncbi.nlm.nih.gov/pubmed/26426911

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Warner EL, Kirchhoff AC, Nam GE, et al.. Financial burden of pediatric cancer for patients and their families. J Oncol Pract 2015;11:12–18. https://www.ncbi.nlm.nih.gov/pubmed/25316026

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Mikulska M, Lanini S, Gudiol C, et al.. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 2018;24(Suppl 2):S71–S82. https://www.ncbi.nlm.nih.gov/pubmed/29447988

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 97.

    Barmettler S, Ong MS, Farmer JR, et al.. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 2018;1:e184169. https://www.ncbi.nlm.nih.gov/pubmed/30646343

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Derinkuyu BE, Boyunağa Ö, Öztunalı Ç, et al.. Imaging features of Burkitt lymphoma in pediatric patients. Diagn Interv Radiol 2016;22:95–100. https://www.ncbi.nlm.nih.gov/pubmed/26611257

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Fallon SC, Redell MS, El-Bietar J, et al.. Intestinal perforation after treatment of Burkitt’s lymphoma: case report and review of the literature. J Pediatr Surg 2013;48:436–440. https://www.ncbi.nlm.nih.gov/pubmed/23414881

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Pession A, Masetti R, Gaidano G, et al.. Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel. Adv Ther 2011;28:684–697. https://www.ncbi.nlm.nih.gov/pubmed/21779956

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 101.

    Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011;364:1844–1854. https://www.ncbi.nlm.nih.gov/pubmed/21561350

  • 102.

    Galardy PJ, Hochberg J, Perkins SL, et al.. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children’s Oncology Group Report. Br J Haematol 2013;163:365–372. https://www.ncbi.nlm.nih.gov/pubmed/24032600

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Coiffier B, Altman A, Pui CH, et al.. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767–2778. https://www.ncbi.nlm.nih.gov/pubmed/18509186

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Cairo MS, Coiffier B, Reiter A, et al.. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010;149:578–586. https://www.ncbi.nlm.nih.gov/pubmed/20331465

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2020 by the National Comprehensive Cancer Network 2020
Page Numbers:
19
Article Category:
Other
Print Publication Date:
01 Aug 2020
Online Publication Date:
Aug 2020
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4892 1111 80
PDF Downloads 2979 931 80
EPUB Downloads 0 0 0